SEBI Reg. Investment Advisor

Download App

Help Center Pricing

Recent:

Akums Drugs and Pharmaceuticals gains on reporting consolidated net profit of Rs 75.14 crore in Q4

Akums Drugs & Pharmaceuticals Ltd. | Pharmaceuticals & Drugs | Healthcare | BSE: 544222 | NSE: AKUMS

27 May 2025 Evaluate

Akums Drugs & Pharmaceuticals is currently trading at Rs. 585.60, up by 3.55 points or 0.61% from its previous closing of Rs. 582.05 on the BSE.

The scrip opened at Rs. 596.00 and has touched a high and low of Rs. 620.00 and Rs. 585.00 respectively. So far 90388 shares were traded on the counter.

The BSE group 'B' stock of face value Rs. 2 has touched a 52 week high of Rs. 1174.85 on 20-Aug-2024 and a 52 week low of Rs. 407.40 on 07-Apr-2025.

Last one week high and low of the scrip stood at Rs. 620.00 and Rs. 556.00 respectively. The current market cap of the company is Rs. 9254.77 crore.

The promoters holding in the company stood at 75.26%, while Institutions and Non-Institutions held 13.17% and 11.58% respectively.

Akums Drugs and Pharmaceuticals has reported net profit of Rs 27.59 crore for fourth quarter ended March 31, 2025 as compared to net loss of Rs 57.87 crore for the same quarter in the previous year. The total income of the company increased by 11.01% at Rs 360.80 crore for Q4FY25 as compared to Rs 325.02 crore for the corresponding quarter previous year.

On consolidated basis, the company has reported net profit of Rs 75.14 crore for fourth quarter ended March 31, 2025 as compared to net loss of Rs 32.88 crore for the same quarter in the previous year. The total income of the company increased by 12.43% at Rs 1073.09 crore for Q4FY25 as compared to Rs 954.45 crore for the corresponding quarter previous year.

For the year ended March 31, 2025, the company has reported net profit of Rs 161.00 crore as compared to net loss of Rs 165.45 crore for the previous year. However, total income of the company decreased by 6.65% at Rs 1435.98 crore for year under review as compared to Rs 1538.24 crore for year ended March 31, 2024.

For the year ended March 31, 2025, on the consolidated basis, the company has reported net profit of Rs 345.25 crore as compared to net loss of Rs 45.28 crore for the previous year. However, total income of the company decreased by 1% at Rs 4170.28 crore for year under review as compared to Rs 4212.21 crore for year ended March 31, 2024.

Akums Drugs & Pharma Share Price

534.10 0.75 (0.14%)

21-Apr-2026 16:59 View Price Chart

Peers

Company Name	CMP
Sun Pharma Inds.	1665.25
Dr. Reddys Lab	1220.75
Cipla	1232.90
Zydus Lifesciences	928.85
Lupin	2311.75
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Fiduciary-first advisory model.
As SEBI-registered IAs, we are legally and ethically bound to act in the best interests of our clients. We do not sell or distribute any financial products. This ensures our guidance is 100% unbiased and conflict-free.
Deep fundamental research + robust valuation discipline.
Built on more than 15 years of equity research, our framework combines quality assessment, intrinsic value estimation, and a sensible margin-of-safety approach.
Process—not predictions.
We don’t rely on guesswork or market timing. Instead, we focus on asset allocation, risk management, and long-term compounding.
Technology + Human Intelligence.
We believe a combination of both is essential for investing success. We constantly innovate and upgrade in-house tools, financial X-rays, and portfolio analytics so that our team of analysts and advisors are equipped with the best.
Partner with Clients.
We follow a DIWM (Do-It-With-Me) approach where we partner clients in setting goals, financial planning, educating on our investing process and share decision-enabling resources transparently with our clients who retain control on execution.

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

Investing in stocks, mutual funds, debt, and gold
Quality-at-Reasonable-Price way of investing in stocks
Constructing Direct Stock Portfolios with Core, Booster, and Amplifier stocks
A Mutual Fund Portfolio that delivers consistent out-performance and meaningful diversification (low overlap)
Periodic review and rebalancing
Clear Buy-Sell-Hold, and Position-sizing frameworks

PROPRIETARY FRAMEWORK

Portfolio
Architecture >
Stock Picking.

Stop managing a collection of "tips." Access the ABC Framework to build a portfolio that survives cycles and compounds wealth.

Core for Stability

Booster for Alpha

Amplifier for Exponential Wealth

Build a Stress-Tested Portfolio.

Our Sapphire Advisory uses the ABC Concept to ensure you never have to panic during a market correction.

Core Stocks

STABILITY

Booster Stocks

GROWTH

Amplifier Stocks

ASYMMETRY

● Conflict-Free ● SEBI Registered ● 15Y+ Track Record

Access Sapphire ABC Strategy →

Limited Capacity for New Fiduciary Partners

Akums Drugs and Pharmaceuticals gains on reporting consolidated net profit of Rs 75.14 crore in Q4

MoneyWorks4Me Premium

Follow us at

MoneyWorks4Me

About MoneyWorks4Me

Our Vision

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

Name of the IA registered with SEBI:	The Alchemists Ark Pvt. Ltd.
Logo:
Trade/Brand Name of IA:	MoneyWorks4Me Investment Advisers
Brand Logo:
SEBI Registration Number:	INA000013323 Validity – May 16, 2019 – Perpetual
Registration:	Non-Individual
BSE Enlistment No:	1187
Address:	B-101, Signet Corner Building, Balewadi Phata, Baner, Pune, Maharashtra 411045
Compliance officer Details:	Name: Shrikant Jagtap Email: shrikant.jagtap@moneyworks4me.com Telephone: +919860359463 Address: Same as IA
Grievance Officer Details:	Name: Mukta Vaze Email: mukta.vaze@moneyworks4me.com Telephone: +91 98609 19463 Address: Same as IA
Principal Officer Details:	Name: Atharva Bhide Email: atharva.bhide@moneyworks4me.com Telephone: +91 91758 99463 Address: Same as IA
Standard Warning:	Investment in securities market are subject to market risks. Read all the related documents carefully before investing.
Disclaimer:	Registration granted by SEBI, enlistment with exchange and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.